Can a flexible dosing schedule improve esophageal cancer treatment?
NCT ID NCT07733180
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether giving the immunotherapy drug tislelizumab every 2 weeks or every 4 weeks, alongside standard chemotherapy, is safe and effective for Japanese patients with advanced esophageal cancer that cannot be removed by surgery. The study aims to find the best dosing schedule to control the disease and reduce side effects. All participants have not received prior treatment for their advanced cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tislelizumab plus chemotherapy (oxaliplatin, leucovorin, 5-fluorouracil)
- What this could lead to
- If successful, this could help identify a more convenient or effective dosing schedule for tislelizumab in treating advanced esophageal cancer.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply broadly. The combination therapy may cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug boost the fight against esophageal cancer?
- Experimental combo targets Hard-to-Treat esophageal cancer
- New drug cocktail targets Hard-to-Treat cancers
- New drug YL201 takes on tough esophageal cancer
- Smart MRI tailors cancer therapy for better outcomes
- New drug cocktail aims to fight tough esophageal cancer